NEW YORK--(BUSINESS WIRE)--INNOVIVE Pharmaceuticals, Inc. today announced that, based on results of a Phase 1 clinical trial, it will discontinue development of INNO-105.
“After careful review of trial results, we have decided to concentrate our resources on the rest of our oncology pipeline and to seek more promising compounds,” said Steven Kelly, President and Chief Executive Officer, INNOVIVE.
